- Conditions
- Auricular Stimulation
- Interventions
- Transcutaneous Auricular Neurostimulation (tAN)
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,656
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peripheral Arterial Disease
- Interventions
- Control/Sham Treatment, Heat Therapy
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Major Depressive Disorder, Anhedonia
- Interventions
- Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
- Device
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Obesity
- Interventions
- FB Professional LED Red light therapy, Effects of Red Light LED Therapy on Body Contouring
- Device
- Lead sponsor
- Manamed Inc.
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New Port Richey, Florida
- Conditions
- Opioid Withdrawal, Pain, Craving
- Interventions
- Active BRIDGE device placement, Inactive BRIDGE device placement
- Device
- Lead sponsor
- BrightView LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Migraine, Cannabis, THC, CBD
- Interventions
- THC ~5%, CBD ~12%, THC ~5% and CBD ~12%, Sham Cannabis
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Healthy, Pain
- Interventions
- Selective Nerve Stimulation (SNS) stimulator device
- Device
- Lead sponsor
- Codman & Shurtleff
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Raynham, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Selective Venography followed by therapeutic balloon angioplasty, Control arm
- Device · Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pain
- Interventions
- Percutaneous radiofrequency electrical nerve stimulation, Non-therapeutic stimulation
- Device
- Lead sponsor
- Synaptrix, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Daphne, Alabama • Williamsville, New York • Chapel Hill, North Carolina + 2 more
- Conditions
- Mild to Moderate Hypertension
- Interventions
- electroacupuncture
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Irvine, California • Orange, California
- Conditions
- Acute Pain, Regional Anesthesia Morbidity
- Interventions
- ropivacaine, bupivacaine, Sham Adductor Canal Catheter, Adductor Canal Catheter
- Drug · Device
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 40 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinomas, Squamous Cell, Dysphagia
- Interventions
- Acupuncture
- Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Erectile Dysfunction
- Interventions
- Injection of adipose derived cells into penis
- Device
- Lead sponsor
- Tissue Genesis
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Gainesville, Florida + 2 more
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Bipolar Disorder
- Interventions
- tACS brain stimulation treatment, Sham stimulation treatment
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hypertension, High Blood Pressure
- Interventions
- ROX Coupler, Sham procedure
- Device · Other
- Lead sponsor
- ROX Medical, Inc.
- Industry
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI insert, Sham injection
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
- Conditions
- Glaucoma
- Interventions
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops
- Drug · Procedure · Other
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas
- Conditions
- Cerebellar Ataxia, Cerebellar Diseases, Cerebellar Stroke, Cerebellar Tumor
- Interventions
- Therapy
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Scleroderma, Systemic
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- Intermittent Hypoxia, Normoxia
- Interventions
- Intermittent Hypoxia, Normoxia (sham)
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pain During Saline Infusion Sonogram
- Interventions
- Lidocaine, Sham paracervical block
- Drug · Procedure
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hartsdale, New York
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis
- Interventions
- standard acupuncture treatment, Control Sham/Minimal Acupuncture
- Device
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Macular Degeneration
- Interventions
- rhuFab V2 (ranibizumab)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Denver, Colorado